10.5 C
Bucharest
October 5, 2022
BUSINESSCOMPANIESECONOMYFINANCE&BANKINGHEALTHINVESTMENTSSocialSOCIAL & HEALTH

PD Neurotechnology, a MedTech start-up for patients suffering from Parkinson’s Disease, is targeting €500.000 in the financing round opened by SeedBlink

PD Neurotechnology operates in 13 European countries, and the USA launch is planned for 2022

 PD Neurotechnology, a MedTech start-up for patients suffering from Parkinson’s Disease, the second most common neurologic disease in the world, is targeting €500.000 in the financing round opened by SeedBlink, the European co-investment platform in tech startups.

This €5.000,000 Series A round is led by CIC Capital Partners, the co-investment from CIC Capital Partners & BigPi is of €4.500,000. The PD Neurotechnology’s pre-money valuation is of €30.000,000.

The funds raised in this investment round will be used for manufacturing purposes, clinical trials and to boost business development in new markets.

PD Neurotechnology is providing people with Parkinson’s Disease and other movement disorders with affordable, easy-to-use medical wearables and advanced AI software for monitoring and treatment, which can be applied at home or in non-clinical settings. The PD Neurotechnology’s team includes 40 specialists in biomedical devices, neurology, healthcare, logistics, artificial intelligence and Parkinson’s Disease, and has a world-class advisory board of leading neurology and Parkinson’s
disease scientists.

PD Neurotechnology’s first product, PDMonitor, is a CE marked class IIa medical device, consisting of monitoring devices/wearables, which capture and show raw motion data from predefined body locations, a Smart Box, which processes motion data and extracts PD symptoms, and a PD Monitor Cloud, which merges symptoms and mobile app input into a powerful knowledge base, thus making patient management more effective. The Physician tool is a powerful disease management tool and electronic patient record which helps the treating physician access this data, supporting disease staging and treatment optimization.

Nikos Moschos, Founder & Business Director of PD Neurotechnology said: “We are very proud of our multisensory approach and system architecture, which ensures that Parkinson’s Disease symptoms are continuously monitored in a user-friendly manner, enabling prompt support and treatment optimization. Our goal has always been to develop innovative and non-invasive solutions to help patients feel safer, and forge a close and effective doctor-patient relationship. Our plans for the future are substantial, we are constantly looking for new sources of growth and we always seek to diversify and enhance the solutions we provide.”

Ionuț Pătrăhău, Managing Director & Corporate Development at SeedBlink said: “It is important that we back MedTech innovators, as they not only impact the economy, but they improve people’s lives. We need to strengthen their ability to provide efficient solutions. Meaningful innovation makes our investment all the more meaningful. We are enthusiastic about PD Neurotechnology’s products and are keen to support their growth.”

PD Neurotechnology is a Greek digital health company founded in London in 2015, by Prof. Dimitris Fotiadis – Technical Director, Prof. Spyridon Konitsiotis – Medical Director, MD, PhD, Nikos Moschos – Business Director, and Tassos Manos – Board member.

About SeedBlink 

 

SeedBlink is a tech specialized venture investment platform that enables business leaders to fund top-tier European tech startups and scale-ups alongside established institutional investors. SeedBlink’s mission is to build an efficient investment infrastructure for individual and institutional investors to work together to fund innovative European technology companies.

Launched in early 2020, SeedBlink has attracted over 12,000 individual investors from 60 countries and has a portfolio of 60 funded companies from 12 countries. Funding rounds in which platform users have participated as co-investors include FlowX with €1.6 million (€7.3 million round), Dronamics with €950,000 (€3 million round) and Hunch with €550,000 (€3 million round).

Investing in start-ups involves risks, including loss of invested capital, lack of liquidity, dilution and lack of dividends. Some of the ways to mitigate risk are to diversify investments and to focus on areas where investors have experience and/or companies in whose products they strongly believe.

 

About PD Neurotechnology

 

PD Neurotechnology is a Greek digital health company founded in London in 2015, by by a team of experts in patient monitoring systems for movement disorders, consisting of  Prof. Dimitris Fotiadis – Technical Director, Prof. Spyridon Konitsiotis – Medical Director, MD, PhD, Nikos Moschos – Business Director, and Tassos Manos – Board member.Prof.

Sales and marketing is based in Athens, Greece, and R&D and production in Ioannina, Greece. The company operates in 13 European countries, and the USA launch is planned for 2022.

 PD Neurotechnology focuses on the research, development, production, distribution, sales and marketing of systems and services, which include but are not limited to, medical devices, sensors and software for the monitoring, diagnosis and treatment of patients suffering from Parkinson’s disease and other movement disorders.

PD Neurotechnology has established a high-quality infrastructure, a team of 40 specialists in biomedical devices, neurology, healthcare, logistics, artificial intelligence and Parkinson’s Disease, and has a world-class advisory board of leading neurology and Parkinson’s disease scientists.

 

Related posts

MerchantPro analysis: Recent events in Ukraine are slowing down the dynamics of online stores

NINE O'CLOCK

Gov’t: Total guarantee ceiling on First Home 2017 programme is set at 2.67 billion lei

Nine O' Clock

3,000 pilgrims pay homage to St. Andrew’s relics

Nine O' Clock